CONSOLIDATED STATEMENTS OF INCOME (unaudited) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||||
|---|---|---|---|---|---|---|
Sep. 30, 2024 |
Sep. 30, 2023 |
Sep. 30, 2024 |
Sep. 30, 2023 |
|||
| Income Statement [Abstract] | ||||||
| Dialysis patient service revenues | $ 3,138,561 | $ 2,951,950 | $ 9,141,195 | $ 8,602,669 | ||
| Other revenues | 125,029 | 169,382 | 379,672 | 391,731 | ||
| Total revenues | 3,263,590 | 3,121,332 | 9,520,867 | 8,994,400 | | |
| Operating expenses: | ||||||
| Patient care costs | 2,151,875 | 2,067,315 | 6,373,150 | 6,181,348 | ||
| General and administrative | 393,534 | 376,883 | 1,123,859 | 1,072,513 | ||
| Depreciation and amortization | 187,014 | 188,423 | 549,758 | 550,166 | ||
| Equity investment income, net | (3,711) | (7,228) | (15,874) | (22,502) | ||
| Gain on changes in ownership interest | 0 | 0 | (35,147) | 0 | ||
| Total operating expenses | 2,728,712 | 2,625,393 | 7,995,746 | 7,781,525 | | |
| Operating income | 534,878 | 495,939 | 1,525,121 | 1,212,875 | | |
| Debt expense | (134,583) | (98,080) | (331,748) | (302,361) | | |
| Debt prepayment, extinguishment and modification costs | (10,081) | 0 | (19,813) | (7,962) | | |
| Other loss, net | (16,780) | (19,650) | (56,900) | (14,525) | | |
| Total Other Income Expenses | -161444.0 | -117730.0 | -408461.0 | -324848.0 | 0 | |
| Income before income taxes | 373,434 | 378,209 | 1,116,660 | 888,027 | | |
| Income tax expense | 77,674 | 68,848 | 215,168 | 161,621 | | |
| Net income | 295,760 | 309,361 | 901,492 | 726,406 | | |
| Less: Net income attributable to noncontrolling interests | (81,072) | (62,729) | (224,479) | (185,536) | ||
| Net income attributable to DaVita Inc. | $ 214,688 | $ 246,632 | $ 677,013 | $ 540,870 | ||
| Earnings per share attributable to DaVita Inc.: | ||||||
| Basic net income | $ 2.56 | $ 2.70 | $ 7.86 | $ 5.95 | ||
| Diluted net income | $ 2.50 | $ 2.62 | $ 7.66 | $ 5.80 | ||
| Weighted average shares for earnings per share: | ||||||
| Basic shares | 83,721,000 | 91,322,000 | 86,123,000 | 90,937,000 | ||
| Diluted shares | 85,795,000 | 94,041,000 | 88,422,000 | 93,317,000 | ||
| X | ||||||||||
- Definition Debt Prepayment, Extinguishment And Modification Costs No definition available.
|
| X | ||||||||||
- Definition Patient care costs are costs directly associated with operating and supporting dialysis centers, medical clinics and ancillary operations and consist principally of labor, pharmaceuticals, medical supplies and facility operating costs. No definition available.
|
| X | ||||||||||
- Definition Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts No definition available.
|
| X | ||||||||||
- Definition In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Total costs of sales and operating expenses for the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of income (loss) for proportionate share of equity method investee's income (loss). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Interest and debt related expenses associated with nonoperating financing activities of the entity. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of Net Income (Loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of revenue and income classified as other. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|